Fabian Gerlinghaus (Cellares)

A cou­ple months af­ter land­ing $100 mil­lion in fund­ing, Cel­lares grabs part­ner for its Cell Shut­tle

The team at Cel­lares hopes that its Cell Shut­tle is the fu­ture of end-to-end cell ther­a­py man­u­fac­tur­ing. On Wednes­day, the com­pa­ny an­nounced that one more com­pa­ny has signed up to work along­side it.

Po­sei­da has signed on to pro­vide ther­a­pies for the Cell Shut­tle, a portable fac­to­ry Cel­lares hopes will dis­rupt the ex­pen­sive and lo­gis­ti­cal­ly com­pli­cat­ed cell ther­a­py man­u­fac­tur­ing process. The com­pa­ny is the third to ink a deal with Cel­lares, which is based out of South San Fran­cis­co, CA. Cel­lares has al­ready has been col­lab­o­rat­ing with PACT Phar­ma and the Fred Hutchin­son Can­cer Re­search Cen­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.